Michel A Duchosal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7440897/publications.pdf

Version: 2024-02-01

30 papers	8,759 citations	567281 15 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	21217 citing authors

#	Article	IF	Citations
1	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncology, 2022, 8, e220446.	7.1	48
2	Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia. Cell Death and Disease, 2022, 13, 320.	6.3	5
3	Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery. Pharmaceuticals, 2022, 15, 848.	3.8	10
4	Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland. Blood Transfusion, 2020, 18, 446-453.	0.4	1
5	Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives. Journal of Oncology, 2019, 2019, 1-16.	1.3	16
6	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. Cell Stem Cell, 2019, 24, 405-418.e7.	11.1	143
7	Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent. Oncotarget, 2019, 10, 6723-6738.	1.8	19
8	Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly, 2019, 149, w20031.	1.6	4
9	Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells. European Journal of Medicinal Chemistry, 2018, 150, 457-478.	5.5	6
10	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. Haematologica, 2018, 103, 80-90.	3.5	48
11	Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability. International Journal of Molecular Sciences, 2018, 19, 2621.	4.1	7
12	Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 translation. Journal of Clinical Investigation, 2018, 128, 1597-1614.	8.2	20
13	Diagnosis and treatment of follicular lymphoma: an update. Swiss Medical Weekly, 2018, 148, w14635.	1.6	12
14	Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997â€“2016. Swiss Medical Weekly, 2018, 148, w14589.	1.6	2
15	Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. Cancer Research, 2017, 77, 3857-3869.	0.9	81
16	Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. Nutrition, 2017, 35, 43-50.	2.4	39
17	Gray platelet syndrome: Novel mutations of the NBEAL2 gene. American Journal of Hematology, 2017, 92, E20-E22.	4.1	12
18	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701

#	Article	IF	Citations
19	Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis. PLoS ONE, 2016, 11, e0163542.	2.5	15
20	Combinative effects of Î²-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation. Biochimie, 2015, 116, 141-153.	2.6	14
21	Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Medical Weekly, 2015, 145, w14100.	1.6	5
22	The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody. Leukemia and Lymphoma, 2014, 55, 2141-2150.	1.3	15
23	A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis. Autophagy, 2014, 10, 603-617.	9.1	28
24	A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. Journal of Hematology and Oncology, 2014, 7, 33.	17.0	29
25	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
26	Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. Bioorganic and Medicinal Chemistry, 2011, 19, 7720-7727.	3.0	13
27	Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as Î±-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorganic and Medicinal Chemistry, 2010, 18, 3320-3334.	3.0	24
28	The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood, 2009, 113, 3276-3286.	1.4	168
29	Endogenous Angiotensin II Induces Atherosclerotic Plaque Vulnerability and Elicits a Th1 Response in ApoE â^'/â^' Mice. Hypertension, 2004, 44, 277-282.	2.7	123
30	Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. European Journal of Immunology, 2000, 30, 2065-2073.	2.9	29